GLP-1 FamilyBlend / Stack

Cagrisema (Cagrilintide + Semaglutide)

Fixed-combination amylin analog plus GLP-1 receptor agonist

A research-supplier blend combining the amylin analog cagrilintide with the GLP-1 receptor agonist semaglutide, referenced in combination metabolic-research contexts.

Also referenced as: CagriSema, Cagrilintide + semaglutide

t½ ~7 days (both components)Blend

Overview

An investigational fixed-dose combination developed by Novo Nordisk that co-formulates the amylin analog cagrilintide with the GLP-1 receptor agonist semaglutide. It has been evaluated in clinical trials in the 2020s.

At a glance

ClassFixed-combination amylin analog plus GLP-1 receptor agonist

CategoryGLP-1 Family

Half-life~7 days (both components)

Typical formLyophilized powder

AliasesCagriSema, Cagrilintide + semaglutide

Use designationResearch / in-vitro only

Regulatory statusInvestigational; not approved by the FDA or EMA. Under evaluation in clinical trials.

What Cagrisema (Cagrilintide + Semaglutide) does

CagriSema is a fixed-combination of two peptides — cagrilintide (a long-acting amylin receptor agonist) and semaglutide (a GLP-1 receptor agonist) — co-formulated for once-weekly use. Its rationale is mechanistic complementarity: the two components act on distinct satiety systems. Semaglutide drives glucose-dependent insulin secretion, glucagon suppression, slowed gastric emptying, and hypothalamic/hindbrain appetite reduction through the GLP-1 receptor, while cagrilintide engages amylin receptors in the area postrema and is implicated in restoring leptin sensitivity. Because these pathways are largely non-overlapping, the combination is designed to suppress appetite and reduce body weight more than either agent alone.

In the REDEFINE phase 3 obesity program, CagriSema produced substantial weight loss — REDEFINE-1 reported roughly 22-23% mean body-weight reduction over 68 weeks in people with obesity without diabetes, and REDEFINE-2 showed strong (somewhat smaller) reductions in people with type 2 diabetes. A notable trial finding was that a large share of the effect depended on participants reaching top doses of both components, which shaped interpretation of the headline numbers. Beyond weight, the combination lowers blood glucose and improves cardiometabolic markers through the semaglutide arm. CagriSema is investigational, with human phase 3 data; regulatory review is ongoing and long-term outcomes are still maturing. Its distinguishing feature is being a dual-hormone (amylin + GLP-1) combination rather than a single multi-receptor molecule.

Effects reported in research

Combined amylin (cagrilintide) and GLP-1 (semaglutide) receptor agonism acting on complementary satiety pathways (mechanistic / human clinical).
~22-23% mean body-weight reduction over 68 weeks in obesity without diabetes in REDEFINE-1 (human clinical, phase 3).
Substantial weight loss in type 2 diabetes participants in REDEFINE-2, somewhat less than in the non-diabetic population (human clinical).
Greater appetite suppression than either component alone due to non-overlapping mechanisms (mechanistic / human clinical).
Improved glycemic control and cardiometabolic markers via the semaglutide component (human clinical).
Slowed gastric emptying from both the GLP-1 and amylin arms (human clinical).
Effect magnitude tied to reaching top maintenance doses of both components in trials (human clinical observation).
Long-term outcomes and regulatory status still maturing — investigational, phase 3 (investigational).

Effects listed reflect findings reported in the research literature — many in animal or in-vitro models. Listing an effect is not a claim of efficacy or a therapeutic indication in humans.

Mechanism of action

CagriSema combines two complementary mechanisms in a single formulation: cagrilintide, a long-acting amylin analog acting on amylin/calcitonin receptors, and semaglutide, a GLP-1 receptor agonist. The amylin component promotes satiety and slows gastric emptying, while the GLP-1 component enhances glucose-dependent insulin secretion, suppresses glucagon, and reduces appetite. The two are intended to act on distinct but complementary appetite- and glucose-regulating pathways.

Mechanistic description reflects published research-literature understanding. Much peptide research is preclinical (in-vitro or animal-model); mechanism in humans may differ and is not established for many compounds.

What it's studied for

Research contexts in which Cagrisema (Cagrilintide + Semaglutide) appears in the literature. Listing a research area is not a claim of efficacy or a therapeutic indication.

Key characteristics

A co-formulated combination, not a single novel molecule, pairing cagrilintide with semaglutide
Combines two distinct mechanisms: amylin-receptor agonism and GLP-1-receptor agonism
Both components are long-acting and support once-weekly subcutaneous administration
Designed to leverage complementary appetite-regulating pathways
Evaluated in the REDEFINE clinical trial program for obesity and diabetes

Reported research dosing reference only

Educational reference, not dosing guidance. The figures below summarize amounts reported in published research and research-community protocols, provided for educational and research context only. They are not medical advice, not a recommendation, and not instructions for human use. Cagrisema (Cagrilintide + Semaglutide) is a research compound.

CagriSema is a 1:1 fixed-dose combination of cagrilintide and semaglutide dosed once weekly, escalated in matched steps to a 2.4 mg / 2.4 mg target. These are reference figures describing published research/protocols, not dosing guidance for humans.

Lead once-weekly combination: cagrilintide 2.4 mg + semaglutide 2.4 mg (1:1 ratio)
Escalation uses matched lower steps of both components before the 2.4/2.4 mg target

Reported frequencyOnce weekly (subcutaneous in the reported protocols)

ReconstitutionAs a two-peptide blend, reconstituted with bacteriostatic water; refrigerate and protect from light after reconstitution.

Both components have ~7-day half-lives, matching the weekly schedule. Investigational combination. Reference figures for research context only.

How it compares

CagriSema is distinguished by being a fixed combination of an amylin analog and a GLP-1 agonist, rather than a single-molecule mono-, dual-, or triple-agonist.

Blend components

This entry documents a research-supplier blend combining the following. Each component is documented as its own PeptiDex entry where available:

CagrilintideGLP-1 Family SemaglutideGLP-1 Family

Commonly studied alongside

Compounds frequently researched together with Cagrisema (Cagrilintide + Semaglutide) in the literature. Cross-referenced for research context — not a usage or combination recommendation.

CagrilintideThe amylin-analogue component of the CagriSema blend.SemaglutideThe GLP-1-agonist component of the CagriSema blend.

Compare and calculate

Side-by-side pages for the pairings the literature already documents for Cagrisema (Cagrilintide + Semaglutide), plus the unit-conversion reference for a reconstituted vial. Factual comparisons of documented characteristics — not a recommendation to combine or use any compound.

Handling & Stability

Lyophilized peptides are stored cold, protected from light, and reconstituted only at the time of intended in-vitro work.

Avoid repeated freeze-thaw cycles
Verify supplier lot and Certificate of Analysis
Follow institutional lab-safety protocols

Analytical & COA Concepts

Reputable research suppliers publish a third-party Certificate of Analysis per batch. Key analytical concepts referenced in COAs include:

Category Context

Cagrisema (Cagrilintide + Semaglutide) sits in the GLP-1 Family area of the PeptiDex library.

Research Supplier Listing

Where researchers source Cagrisema (Cagrilintide + Semaglutide)

For researchers studying Cagrisema (Cagrilintide + Semaglutide), third-party suppliers such as Practically Natty Peptides offer research-grade material, third-party tests every batch and provides Certificates of Analysis on request, and ship from the US.

Explore Research Suppliers →

PeptiDex does not maintain a direct supplier listing for this compound. The link above goes to a third-party research-supplier directory.

Frequently asked questions

What is CagriSema and what two compounds is it made of?

CagriSema is a fixed-dose combination of the amylin analogue cagrilintide and the GLP-1 agonist semaglutide, co-formulated for once-weekly administration. It pairs two distinct mechanisms — amylin/calcitonin-receptor signaling plus GLP-1-receptor signaling — in a single injection. It is studied in obesity and metabolic models where the combination showed larger weight effects than either component alone.

What is the ratio of cagrilintide to semaglutide in CagriSema?

The lead combination is a 1:1 ratio, CagriSema 2.4 mg / 2.4 mg — 2.4 mg of cagrilintide plus 2.4 mg of semaglutide once weekly. Lower matched steps are used during escalation. In the REDEFINE 1 data the 2.4/2.4 mg combination produced greater mean weight reduction than either cagrilintide 2.4 mg or semaglutide 2.4 mg alone.

Why are the two components a good pharmacokinetic match?

Both cagrilintide (~7-8 day half-life) and semaglutide (~7 day half-life) are engineered for once-weekly dosing, so they can be co-administered on the same weekly schedule. Their similar kinetics are part of why the fixed-dose combination is practical. Study designs use a matched multi-week escalation for both components together.

How is CagriSema dose-escalated in the literature?

Reported protocols escalate the two components together in matched weekly steps up to the 2.4 mg / 2.4 mg target, mirroring the individual escalation schedules of semaglutide and cagrilintide to manage gastrointestinal tolerability. These are reference figures for research context only, not human dosing guidance.

Is CagriSema an approved drug?

As of the current literature CagriSema is investigational — its phase 3 REDEFINE program has reported results and a regulatory filing has been made, but it is not yet an approved product. It should be handled strictly as a research reference, not for human use.

How does CagriSema differ from semaglutide alone?

CagriSema adds the amylin analogue cagrilintide on top of semaglutide, engaging a second appetite/satiety pathway. In the REDEFINE 1 data the combination produced a larger mean weight reduction (about 22.7%) than semaglutide 2.4 mg alone (about 16.1%). The added component is the whole point of the blend.

Answers are educational summaries of research-literature context and do not constitute medical advice. See the Research Library, COA guide, and Storage & Handling guide for more.

References

Primary literature indexed in PubMed for Cagrisema (Cagrilintide + Semaglutide). Listing a study records that it exists and is indexed — it is not a claim of efficacy, a therapeutic indication, or an endorsement of its conclusions. Much of this literature is preclinical (in-vitro or animal-model).

Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity N Engl J Med, 2025. PubMed 40544433
Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial Lancet, 2023. PubMed 37364590

Each reference was checked against its PubMed record on 2026-07-28: the PMID resolves and the title, journal and year match. Where no indexed literature exists for a compound, PeptiDex says so rather than substituting a citation about a different molecule. See the editorial policy.